Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
A study of biosimilar infliximab-dyyb (CT-P13) in RA found stable disease activity in patients switching from the reference product or another infliximab biosimilar, and improvement in those switching from non-infliximab biologics or tsDMARDs. 68% of patients remained on CT-P13 at 6 months, with 32.9% achieving low disease activity. The study suggests real-world outcomes are comparable to clinical trial efficacy.
Reference News
A study of biosimilar infliximab-dyyb (CT-P13) in RA found stable disease activity in patients switching from the reference product or another infliximab biosimilar, and improvement in those switching from non-infliximab biologics or tsDMARDs. 68% of patients remained on CT-P13 at 6 months, with 32.9% achieving low disease activity. The study suggests real-world outcomes are comparable to clinical trial efficacy.